Evidence map›Paper›PMID 32655552›Full record

ArticleFrontiers in immunology2020

A Critical Blimp-1-Dependent IL-10 Regulatory Pathway in T Cells Protects From a Lethal Pro-inflammatory Cytokine Storm During Acute Experimental

Carl De Trez, Benoit Stijlemans, Viki Bockstal, Jennifer Cnops, Hannelie Korf, Jacques Van Snick, Guy Caljon, Eric Muraille, Ian R Humphreys, Louis Boon and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 4 countries.

Carl De TrezResearch Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Benoit StijlemansResearch Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Viki BockstalResearch Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Jennifer CnopsResearch Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Hannelie KorfLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.
Jacques Van Snickde Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Guy CaljonLaboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Wilrijk, Belgium.
Eric MurailleUnité de Recherche en Biologie des Microorganismes, Laboratoire d'Immunologie et de Microbiologie, Université de Namur, Namur, Belgium.
Ian R HumphreysDivision of Infection and Immunity/Systems Immunity University Research Institute, Cardiff University, Cardiff, United Kingdom.
Louis BoonBioceros, Utrecht, Netherlands.
Jo A Van GinderachterResearch Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Stefan MagezResearch Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Vrije Universiteit Brussel · BECardiff University · GBKU Leuven · BELudwig Cancer Research · BEPolpharma Biologics (Netherlands) · NLUniversité Libre de Bruxelles · BEUniversity of Antwerp · BEVIB-UGent Center for Inflammation Research · BE

Funding

Wellcome Trust 207503/Z/17/Z
6 · The paper itself

Abstract

In many infectious diseases, the immune response operates as a double-edged sword. While required for protective immunity, infection-induced inflammation can be detrimental if it is not properly controlled, causing collateral body damage and potentially leading to death. It is in this context that the potent anti-inflammatory cytokine interleukin-10 (IL-10) is required to dampen the pro-inflammatory immune response that hallmarks trypanosomosis. Effective control of this infection requires not just the action of antibodies specific for the parasite's variable surface glycoprotein (VSG) coat antigens, but also a pro-inflammatory immune response mediated mainly by IFNγ, TNF, and NO. However, strict control of inflammation is mandatory, as IL-10-deficient mice succumb from an unrestrained cytokine storm within 10 days of a

Indexed as

Trypanosoma brucei bruceiAnimalsCytokine Release SyndromeDisease Models, AnimalFemaleInflammationInsect VectorsInterleukin-10InterleukinsLiverMaleMiceMice, Inbred C57BLMice, KnockoutPositive Regulatory Domain I-Binding Factor 1SpleenIL10 protein, mouseIl27 protein, mouseInterleukin-10InterleukinsPositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseBlimp-1IL-10IL-27inflammationT. bruceiT cells

Identifiers

PMID32655552
PMCPMC7325990
OpenAlexW3033543837

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.